{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-049856","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2022-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.413502+00:00","generated_at":"2026-06-26T04:34:48.736978+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PN-943 Phase 2 IDEAL study shows 27.5% clinical remission at 150mg BID; 13% delta vs placebo","bullets":["PN-943 150mg BID achieved 27.5% clinical remission vs 14.5% placebo (delta 13%, p=0.08); bio-naïve delta 16% (p=0.04).","Statistically significant histological remission (RHI≤6) at 37.2% vs 14.3% placebo (delta 23%, p=0.0107).","Endoscopic improvement: 43.1% vs 16.4% placebo (delta 26.7%, p=0.0023).","450mg BID showed no efficacy, consistent with bell-shaped dose-response observed for other α4β7 integrin antagonists.","No drug-related SAEs; safety profile similar to placebo; company plans to advance to Phase 3 registrational study."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-049856","json":"https://secwatch.observer/filing/0001104659-22-049856.json","markdown":"https://secwatch.observer/filing/0001104659-22-049856.md","text":"https://secwatch.observer/filing/0001104659-22-049856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922049856/0001104659-22-049856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922049856/tm2213399d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:34:48.736978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}